[ad_1]
October 13, 2023
2 min watch
Healio spoke with Melina Elpi Marmarelis, MD, about key takeaways from the MARS 2 trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
“Surprising to many, the study actually showed that there was a detriment to surgery vs. those who were randomized to systemic therapies,” Marmarelis, who is medical director of the Penn Mesothelioma Program and an assistant professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania, told Healio.
She explained that this was, in part, due to a higher mortality rate associated with surgery compared to previous studies.
“My main takeaways are that surgery is not for everyone, and it doesn’t necessarily yield better outcomes in mesothelioma” Marmarelis said.
She added that clinicians will “be looking a lot more closely at patients who are considering surgery because of this trial.”
Sources/Disclosures
Collapse
Lim E, et al. Abstract PL03.10. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer; Sept. 9-12, 2023; Singapore.
Disclosures:
Marmarelis reports research funding from AstraZeneca (Inst), Eli Lilly (Inst), Genentech (Inst) and Merck (Inst); consulting with Astra Zeneca, Bayer, Boehringer Ingelheim, Blueprint Pharmaceuticals, Bristol Myers Squibb, Ikena, Janssen, Novocure and Takeda; receiving honorarium from Thermo Fisher; and stock from Johnson & Johnson and Merck.
Take Homes in Lung Cancer
|
Sources 2/ https://www.healio.com/news/hematology-oncology/20231013/video-surgery-not-for-everyone-with-mesothelioma-not-linked-to-better-outcomes The mention sources can contact us to remove/changing this article |
[ad_2]